000
| 00899nam##2200229za#4500 |
---|
001 | 9.699923 |
---|
003 | CaOODSP |
---|
005 | 20210625000612 |
---|
007 | cr ||||||||||| |
---|
008 | 150407|2014||||xxc|||||o f|0| 0 eng|d |
---|
020 | |a978-1-100-25022-9 |
---|
040 | |aCaOODSP|beng |
---|
043 | |an-cn--- |
---|
086 | 1 |aH164-184/2014E-PDF |
---|
110 | 1 |aCanada. |bHealth Canada. |
---|
245 | 10|aGuidance document for industry - review of drug brand names |h[electronic resource] |
---|
260 | |aOttawa - Ontario : |bHealth Canada |cJuly 2014. |
---|
300 | |a44p.|bfigs., references, tables |
---|
500 | |a"effective date: June 13, 2015" |
---|
590 | |a14-45|b2014-11-07 |
---|
775 | 08|tLigne directrice à intention de l'industrie - examen des marques nominatives de médicament |w(CaOODSP)9.643864 |
---|
856 | 40|ahttp://publications.gc.ca|qPDF|s314 KB|uhttps://publications.gc.ca/collections/collection_2014/sc-hc/H164-184-2014-eng.pdf |
---|